Holen Sie sich die Stockscreener-App
31.23
0.10%
-0.03
Handel nachbörslich:
31.23
Schlusskurs vom Vortag:
$31.26
Offen:
$31.845
24-Stunden-Volumen:
2.02M
Relative Volume:
1.60
Marktkapitalisierung:
$2.95B
Einnahmen:
$225.27M
Nettoeinkommen (Verlust:
$-140.06M
KGV:
-19.55
EPS:
-1.5974
Netto-Cashflow:
$-87.93M
1W Leistung:
+8.29%
1M Leistung:
+10.28%
6M Leistung:
-6.10%
1J Leistung:
+42.86%
1-Tages-Spanne:
$30.65
$32.34
1-Wochen-Bereich:
$28.90
$32.34
52-Wochen-Spanne:
$20.50
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
31.23 | 2.95B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-09-04 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant - Stock Titan
IDEAYA Biosciences (IDYA) director receives stock options on 20,000 shares - Stock Titan
IDEAYA (IDYA) director receives grant of 20,000 stock options - Stock Titan
IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57 - Stock Titan
IDEAYA (IDYA) director Scott Morrison receives grant of 20,000 stock options - Stock Titan
IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares - Stock Titan
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IDEAYA Biosciences elects Yujiro S. Hata board chairman - grafa.com
IDEAYA Biosciences, Inc. Announces Yujiro S. Hata Elected as Chairman of Board of Directors - marketscreener.com
IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman - marketscreener.com
Cancer research CEO Yujiro Hata now also chairs IDEAYA board - Stock Titan
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
IDEAYA Biosciences Inc (IDYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEAYA Biosciences (IDYA) Surges 4.31%: Breaking Through Resistance Levels?Earnings Beat Stocks - newsline.com
Responsive Playbooks and the IDYA Inflection - Stock Traders Daily
Ideaya Biosciences stock rises on phase 1/2 cancer trial start By Investing.com - Investing.com South Africa
IDEAYA Biosciences enrolls first patient in IDE892 Phase 1/2 trial - grafa.com
Why is Ideaya Biosciences stock rallying today? By Investing.com - Investing.com Canada
Ideaya Biosciences stock rises on phase 1/2 cancer trial start - Investing.com Nigeria
Ideaya begins trial of IDE892 combo in lung, pancreatic cancer - Investing.com
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
New drug combo targets MTAP-deleted pancreatic and lung cancers - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
IDEAYA files shelf offering to raise up to $300M - MSN
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study - Insider Monkey
IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026 - Seeking Alpha
Ideaya Biosciences Stock Crashes 10% Despite Citizens Reiterating Highly Bullish Price Target on Oncology Pipeline - TIKR.com
IDEAYA Biosciences prices $300M public offering of shares and pre-funded warrants at $27/share - MSN
IDEAYA Announces Closing of Public Offering Including Full Exerc - GuruFocus
IDEAYA Biosciences closes $345M public offering By Investing.com - Investing.com South Africa
IDEAYA Biosciences closes $345M public offering - Investing.com
IDEAYA Biosciences raises $323.6M in follow-on offering of common stock and pre-funded warrants - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants - Stock Titan
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
IDEAYA (NASDAQ: IDYA) raises ~$281M via 5.56M shares and pre-funded warrants - Stock Titan
UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Update: IDEAYA Shares Fall After Pricing $300 Million Offering - Moomoo
Peninsula company lines up $345 million stock deal targeting eye cancer - The Business Journals
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving - Benzinga
Ideaya: Expect Offering to Close on or About June 10 >IDYA - Moomoo
Citizens reiterates Ideaya Biosciences stock rating on ASCO data By Investing.com - Investing.com Canada
IDEAYA Biosciences prices $300 million stock offering By Investing.com - Investing.com Australia
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):